Resveratrol Prevents the Development of Pathological Cardiac Hypertrophy and Contractile Dysfunction in the SHR Without Lowering Blood Pressure

Abstract

Resveratrol treatment was beneficial in preventing the development of concentric hypertrophy and cardiac dysfunction in SHR. The cardioprotective effect of resveratrol in SHR may be partially mediated by a reduction in oxidative stress. Thus, resveratrol may have potential in preventing cardiac impairment in patients with essential hypertension.

ε-Viniferin Is More Effective Than Its Monomer Resveratrol in Improving the Functions of Vascular Endothelial Cells and the Heart

“…7,8) Although the compound tended to improve the whole cardiac and LV mass indexes, the effects were not significant. In contrast, "-viniferin significantly reduced SBP and cardiac mass in SHRs.…”

“…The dose of resveratrol was chosen according to previous experimental models using hypertension in SHRs. 7,8) In order to give the same dose of the molecules, the dose of "-viniferin used was the double of that of the monomer. The untreated WKYs and SHRs were administered vehicle orally by gavage (corn oil, Sigma) for the same period.…”

“…5,6) In SHRs, a well-established genetic model of hypertension and subsequent cardiac hypertrophy, resveratrol attenuated the pathological cardiac hypertrophy without lowering blood pressure. 7,8) In contrast, it reduced hypertension in male Sprague-Dawely rats 9) and obese Zucker rats. 10) In contrast to many reports describing the beneficial effects of resveratrol on the vasculature and heart, there are very few reports concerning the beneficial functions of "-viniferin, a natural dehydrodimer of resveratrol.…”

Resveratrol protects rabbit ventricular myocytes against oxidative stress-induced arrhythmogenic activity and Ca2+ overload

“…Over the past two decades, it has been demonstrated from both in vitro and in vivo studies to have cardioprotective effects, including anti-inflammatory, antioxidative, and anti-hyperlipidemic properties as well as the prevention of platelet aggregation and cardiac hypertrophy [12][13][14] . These beneficial effects of resveratrol may provide explanations for the "French paradox", the finding that the consumption of red wine is associated with a decreased incidence of cardiovascular diseases [15] .…”

Why research on resveratrol-mediated cardioprotection should not decelerate1This editorial was invited by the Editors.

“…These include the following: (i) hypertension (Liu et al 2005;Dolinsky et al 2009;Thandapilly et al 2010;Toklu et al 2010;Wojciechowski et al 2010;Chan et al 2011;Rimbaud et al 2011); (ii) obesity (Louis et al 2011;Qin et al 2012 (Barger et al 2008). There is also one study that reported cardioprotection in an animal model of heart failure (Tanno et al 2010).…”